Sprout Pharmaceuticals

Michael Scally MD

Doctor of Medicine
10+ Year Member
Sprout Pharmaceuticals - Sprout Pharmaceuticals, Inc. - Committed to the treatment of female sexual dysfunction (FSD)

FDA Requests 3 New Studies On Pill Aimed At Boosting Female Sex Drive.
FDA asks for more trials of Sprout's drug for low female libido | Reuters

The U.S. Food and Drug Administration has denied an appeal by Sprout Pharmaceuticals to approve its experimental drug for low female sexual desire but offered a potential pathway to approval.

The FDA has asked for three additional studies, two to test the drug's interaction with other drugs, and a third to simulate driving since nearly 10 percent of women in clinical trials became sleepy while taking the drug, flibanserin.

The FDA rejected flibanserin last year saying its effects were "modest" and did not outweigh side effects such as dizziness, nausea and fatigue.
 
'Viagra for Women’ Gets Push for F.D.A. Approval
http://www.nytimes.com/2015/06/01/business/groups-press-fda-to-approve-womens-viagra.html

The drug, flibanserin, has been rejected twice by the F.D.A. on the grounds that its very modest effectiveness was outweighed by side effects like sleepiness, dizziness and nausea. The first rejection, in 2010, followed a decision by a committee of outside advisers to the agency who unanimously opposed approval.

On Thursday, F.D.A. advisers will once again consider whether flibanserin should be approved.
 
FDA Briefing Document - June 4, 2015
Flibanserin (Proposed trade name: Addyi) [Sprout Pharmaceuticals]
Proposed Indication: Treatment of hypoactive sexual desire disorder in premenopausal women
Dosing regimen: 100 mg tablet orally once daily at bedtime
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM449088.pdf
 
Back
Top